clinical trial · NCT06452160
A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
MesotheliomaEpithelioid Hemangioendothelioma(EHE)Solid TumorBGC515
brief summary
The goal of this open-label, dose escalation and dose expansion Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BGC515 administered once daily in 3 weeks cycles in solid tumor patients.
started
Jun 27, 2024
primary completion
Jun 1, 2027
completion
Dec 1, 2027
last updated
Aug 9, 2024
official title
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BGC515 Capsules in Patients With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol